» Articles » PMID: 19293185

The EGF/CSF-1 Paracrine Invasion Loop Can Be Triggered by Heregulin Beta1 and CXCL12

Overview
Journal Cancer Res
Specialty Oncology
Date 2009 Mar 19
PMID 19293185
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

An important step in the process of metastasis from the primary tumor is invasive spread into the surrounding stroma. Using an in vivo invasion assay, we have previously shown that imposed gradients of epidermal growth factor (EGF) or colony-stimulating factor-1 (CSF-1) can induce invasion through an EGF/CSF-1 paracrine loop between cancer cells and macrophages. We now report that invasion induced by other ligands also relies on this EGF/CSF-1 paracrine invasive loop. Using an in vivo invasion assay, we show that MTLn3 breast cancer cells overexpressing ErbB3 exhibit enhanced invasion compared with control MTLn3 cells in response to the ErbB3 ligand HRG-beta1. The invasive response of both MTLn3-ErbB3 and transgenic MMTV-Neu tumors to HRG-beta1 is inhibited by blocking EGF receptor, CSF-1 receptor, or macrophage function, indicating that invasiveness to HRG-beta1 is dependent on the EGF/CSF-1 paracrine loop. Furthermore, we show that CXCL12 also triggers in vivo invasion of transgenic MMTV-PyMT tumors in an EGF/CSF-1-dependent manner. Although the invasion induced by HRG-beta1 or CXCL12 is dependent on the EGF/CSF-1 paracrine loop, invasion induced by EGF is not dependent on HRG-beta1 or CXCL12 signaling, showing an asymmetrical relationship between different ligand/receptor systems in driving invasion. Our results identify a stromal/tumor interaction that acts as an engine underlying invasion induced by multiple ligands.

Citing Articles

The protein circPETH-147aa regulates metabolic reprogramming in hepatocellular carcinoma cells to remodel immunosuppressive microenvironment.

Lan T, Gao F, Cai Y, Lv Y, Zhu J, Liu H Nat Commun. 2025; 16(1):333.

PMID: 39747873 PMC: 11696079. DOI: 10.1038/s41467-024-55577-0.


Key processes in tumor metastasis and therapeutic strategies with nanocarriers: a review.

Li H, Huang H, Tan H, Jia Q, Song W, Zhang Q Mol Biol Rep. 2024; 51(1):197.

PMID: 38270746 DOI: 10.1007/s11033-023-08910-7.


Signaling events at TMEM doorways provide potential targets for inhibiting breast cancer dissemination.

Surve C, Duran C, Ye X, Chen X, Lin Y, Harney A bioRxiv. 2024; .

PMID: 38260319 PMC: 10802469. DOI: 10.1101/2024.01.08.574676.


Targeting macrophages: a novel treatment strategy in solid tumors.

Liu M, Liu L, Song Y, Li W, Xu L J Transl Med. 2022; 20(1):586.

PMID: 36510315 PMC: 9743606. DOI: 10.1186/s12967-022-03813-w.


Reconstructing codependent cellular cross-talk in lung adenocarcinoma using REMI.

Yu A, Li Y, Li I, Ozawa M, Yeh C, Chiou A Sci Adv. 2022; 8(11):eabi4757.

PMID: 35302849 PMC: 8932661. DOI: 10.1126/sciadv.abi4757.


References
1.
Wakeling A, Guy S, Woodburn J, Ashton S, Curry B, Barker A . ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002; 62(20):5749-54. View

2.
Lin E, Nguyen A, Russell R, Pollard J . Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001; 193(6):727-40. PMC: 2193412. DOI: 10.1084/jem.193.6.727. View

3.
Breuleux M . Role of heregulin in human cancer. Cell Mol Life Sci. 2007; 64(18):2358-77. PMC: 11138466. DOI: 10.1007/s00018-007-7120-0. View

4.
Lichtner R, Wiedemuth M, Kittmann A, Ullrich A, Schirrmacher V, Khazaie K . Ligand-induced activation of epidermal growth factor receptor in intact rat mammary adenocarcinoma cells without detectable receptor phosphorylation. J Biol Chem. 1992; 267(17):11872-80. View

5.
Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R . Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res. 2003; 1(3):165-75. View